Literature DB >> 15867773

Laryngotracheoplastic resection for primary tumors of the proximal airway.

Henning A Gaissert1, Hermes C Grillo, Behgam M Shadmehr, Cameron D Wright, Manjusha Gokhale, John C Wain, Douglas J Mathisen.   

Abstract

BACKGROUND: Primary tumors of the airway with proximity to vocal cords and recurrent laryngeal nerves can be resected with sparing of the larynx. Long-term data on survival and local recurrence after laryngotracheal resection are scarce.
METHODS: We conducted a retrospective study of laryngotracheal resection and reconstruction for primary tumors of the airway since 1972.
RESULTS: Twenty-five patients aged 15 to 77 years presented with adenoid cystic carcinomas (n = 9), squamous cell carcinomas (n = 6), and other airway tumors (n = 10). Subglottic resection consisted of anterior cricoid in 5 patients; posterior cricoid mucosa in 9 patients, with resection of the posterior cricoid plate in 3 patients; lateral resection in 7 patients; and combined anterior and posterior elements in 4 patients. Vascularized trachea was tailored to reconstruct the defect. Seven patients without hoarseness required resection of the recurrent laryngeal nerve, and 4 other patients with hoarseness did not. There were no operative deaths. Two (8.0%) patients who had received prior high-dose cervical radiation had anastomotic separation, one requiring laryngectomy. One patient needed permanent tracheostomy, and temporary (<2 months) airway tubes were used in 5 patients. Sixteen patients received postoperative radiation. Median follow-up was 101 months. Four (16%) patients died of disease. Overall survival at 5 and 10 years was 79% and 64%, respectively. No patient underwent laryngectomy for recurrence.
CONCLUSION: Laryngotracheal resection and immediate reconstruction for subglottic tumors is achieved with good preservation of voice, low morbidity, and no compromise of long-term survival.

Entities:  

Mesh:

Year:  2005        PMID: 15867773     DOI: 10.1016/j.jtcvs.2004.07.043

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  The fate of homograft tracheal transplants in sheep.

Authors:  Matthias Behrend; Eva Kluge
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

2.  Overview of malignant tracheal tumors.

Authors:  Maria Lucia L Madariaga; Henning A Gaissert
Journal:  Ann Cardiothorac Surg       Date:  2018-03

3.  Cricotracheal resection for laryngeal invasion by thyroid carcinoma: our experience.

Authors:  Benoît Morisod; Philippe Monnier; Christian Simon; Kishore Sandu
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-16       Impact factor: 2.503

4.  Adenoid Cystic Carcinoma of Trachea.

Authors:  Ashish Varghese; Swati Suneha; John C Watkinson
Journal:  Indian J Surg       Date:  2016-02-13       Impact factor: 0.656

5.  Clinical manifestation and management of primary malignant tumors of the cervical trachea.

Authors:  Youzhong Li; Anquan Peng; Xinming Yang; Zian Xiao; Weijing Wu; Qin Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-03-20       Impact factor: 2.503

6.  Laryngeal preservation in managing advanced tracheal adenoid cystic carcinoma.

Authors:  Thavakumar Subramaniam; Paul Lennon; John Kinsella; James Paul O'Neill
Journal:  Case Rep Otolaryngol       Date:  2015-03-24

Review 7.  Cervical Lymph Node Metastasis in Adenoid Cystic Carcinoma of the Larynx: A Collective International Review.

Authors:  Andrés Coca-Pelaz; Leon Barnes; Alessandra Rinaldo; Antonio Cardesa; Jatin P Shah; Juan P Rodrigo; Carlos Suárez; Jean Anderson Eloy; Justin A Bishop; Kenneth O Devaney; Lester D R Thompson; Bruce M Wenig; Primož Strojan; Marc Hamoir; Patrick J Bradley; Douglas R Gnepp; Carl E Silver; Pieter J Slootweg; Asterios Triantafyllou; Vincent Vander Poorten; Michelle D Williams; Alena Skálová; Henrik Hellquist; Afshin Teymoortash; Jesus E Medina; K Thomas Robbins; Karen T Pitman; Luiz P Kowalski; Remco de Bree; William M Mendenhall; Robert P Takes; Alfio Ferlito
Journal:  Adv Ther       Date:  2016-03-19       Impact factor: 3.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.